Moreover, in these patients, strict glycemic control and DM management through target-specific therapies such as sGLT2 inhibitors and GLP-1 receptor agonists are recommended for reducing the risk of MACE and improving CV outcomes in patients with atherosclerosis, including PAD. The gene discussed is SLC5A2; the disease is atherosclerosis.